The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Cardiovascular disease is associated with poorer outcomes in patients with MPNs
Orly Leiva, MD, NYU Langone Health, New York City, NY, discusses the association between cardiovascular disease (CVD) and myeloproliferative neoplasms (MPNs). Driver mutations for MPNs and clonal hematopoiesis of indeterminate potential (CHIP), including those in JAK2 and TET2, are associated with increased cardiovascular risk. Dr Leiva’s work has shown that the presence of CVD in patients with MPNs leads to poorer outcomes, and he believes collaboration between hematologists and cardiologists could significantly benefit these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
